Japan Market

PuraPharm Japan Co., Ltd., a wholly-owned subsidiary of the PuraPharm Group, is headed by CEO Mr. Fumimoto Bunji, who oversees the Group’s business operations and market expansion in Japan. We are committed to introducing high-quality traditional Chinese medicine products that meet Japanese pharmaceutical standards, including modern formulations such as instant granules and concentrated capsules. Through partnerships with local TCM clinics, we provide integrated diagnosis-and-prescription services, actively promoting the integration of TCM into Japan’s healthcare system.

The Group’s subsidiary, SODX Co., Ltd., operates a health food GMP-certified production facility in Osaka, spanning approximately 1,460 square meters. Equipped with advanced manufacturing technology, the facility produces a variety of formulations including granules, tablets, and capsules. It also serves as an R&D hub focused on developing new products, particularly antioxidants, fermented supplements, and propolis-based health products, continually meeting Japanese market demand for natural, safe, and high-quality wellness solutions.